Integrated analysis of N6-methyladenosine- and 5-methylcytosine-related long non-coding RNAs for predicting prognosis in cervical cancer.
5-methylcytosine
Long non-coding RNAs
N6-methyladenosine
Nomogram
Risk score
Tumor microenvironment
Journal
Hereditas
ISSN: 1601-5223
Titre abrégé: Hereditas
Pays: England
ID NLM: 0374654
Informations de publication
Date de publication:
16 Sep 2024
16 Sep 2024
Historique:
received:
04
07
2024
accepted:
05
09
2024
medline:
17
9
2024
pubmed:
17
9
2024
entrez:
16
9
2024
Statut:
epublish
Résumé
N6-methyladenosine (m Using gene expression data of TCGA set, we identified m We built a co-expression network of 23 m Our study reveals that m
Sections du résumé
BACKGROUND
BACKGROUND
N6-methyladenosine (m
METHODS
METHODS
Using gene expression data of TCGA set, we identified m
RESULTS
RESULTS
We built a co-expression network of 23 m
CONCLUSION
CONCLUSIONS
Our study reveals that m
Identifiants
pubmed: 39285452
doi: 10.1186/s41065-024-00336-w
pii: 10.1186/s41065-024-00336-w
doi:
Substances chimiques
RNA, Long Noncoding
0
Adenosine
K72T3FS567
N-methyladenosine
CLE6G00625
5-Methylcytosine
6R795CQT4H
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
34Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel RLL, Soerjomataram M, Jemal I, Bray A. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49.
doi: 10.3322/caac.21660
Pimple SA, Mishra GA. Global strategies for cervical cancer prevention and screening. Minerva Ginecol. 2019;71(4):313–20.
pubmed: 30808155
doi: 10.23736/S0026-4784.19.04397-1
Shami S, Coombs J. Cervical cancer screening guidelines: an update. JAAPA: Official J Am Acad Physician Assistants. 2021;34(9):21–4.
doi: 10.1097/01.JAA.0000769656.60157.95
Hill EK. Updates in Cervical Cancer Treatment. Clin Obstet Gynecol. 2020;63(1):3–11.
pubmed: 31815773
doi: 10.1097/GRF.0000000000000507
Ward ZJ, Scott AM, Hricak H, Atun R. Global costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis. Lancet Oncol. 2021;22(3):341–50.
pubmed: 33662286
pmcid: 8033570
doi: 10.1016/S1470-2045(20)30750-6
Lin W, Zhou Q, Wang CQ, Zhu L, Bi C, Zhang S, Wang X, Jin H. LncRNAs regulate metabolism in cancer. Int J Biol Sci. 2020;16(7):1194–206.
pubmed: 32174794
pmcid: 7053319
doi: 10.7150/ijbs.40769
Taniue K, Akimitsu N. The functions and unique features of LncRNAs in Cancer Development and Tumorigenesis. Int J Mol Sci. 2021;22(2):1–20.
doi: 10.3390/ijms22020632
Yang Q, Al-Hendy A. The Regulatory functions and the mechanisms of Long non-coding RNAs in Cervical Cancer. Cells 2022, 11(7).
He J, Huang B, Zhang K, Liu M, Xu T. Long non-coding RNA in cervical cancer: from biology to therapeutic opportunity. Biomed Pharmacotherapy = Biomedecine Pharmacotherapie. 2020;127:1–10.
Wang T, Kong S, Tao M, Ju S. The potential role of RNA N6-methyladenosine in Cancer progression. Mol Cancer. 2020;19(1):1–18.
doi: 10.1186/s12943-020-01204-7
Wang Q, Guo X, Li L, Gao Z, Su X, Ji M, Liu J. N(6)-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification. Cell Death Dis. 2020;11(10):1–10.
pubmed: 31911576
pmcid: 6946659
doi: 10.1038/s41419-020-03071-y
Wang H, Luo Q, Kang J, Wei Q, Yang Y, Yang D, Liu X, Liu T, Yi P. YTHDF1 aggravates the progression of Cervical Cancer through m(6)A-Mediated Up-Regulation of RANBP2. Front Oncol. 2021;11:1–13.
Condic M, Ralser DJ, Klümper N, Ellinger J, Qureischi M, Egger EK, Kristiansen G, Mustea A, Thiesler T. Comprehensive analysis of N6-Methyladenosine (m6A) writers, erasers, and readers in Cervical Cancer. Int J Mol Sci. 2022;23(13):1–11.
doi: 10.3390/ijms23137165
Zhang H, Kong W, Zhao X, Han C, Liu T, Li J, Song D. N6-Methyladenosine-related lncRNAs as potential biomarkers for predicting prognoses and immune responses in patients with cervical cancer. BMC Genomic data. 2022;23(1):1–13.
pubmed: 34979907
pmcid: 8725492
doi: 10.1186/s12863-022-01024-2
Nombela P, Miguel-López B, Blanco S. The role of m(6)A, m(5)C and Ψ RNA modifications in cancer: novel therapeutic opportunities. Mol Cancer. 2021;20(1):1–30.
doi: 10.1186/s12943-020-01263-w
Guo G, Pan K, Fang S, Ye L, Tong X, Wang Z, Xue X, Zhang H. Advances in mRNA 5-methylcytosine modifications: detection, effectors, biological functions, and clinical relevance. Mol Therapy Nucleic Acids. 2021;26:575–93.
doi: 10.1016/j.omtn.2021.08.020
Wang L, Zhang J, Su Y, Maimaitiyiming Y, Yang S, Shen Z, Lin S, Shen S, Zhan G, Wang F, et al. Distinct roles of m(5)C RNA methyltransferase NSUN2 in major gynecologic cancers. Front Oncol. 2022;12:1–15.
Zuo Z, Xiong J, Zeng C, Jiang Y, Xiong K, Tao H, Guo Y. Exploration of a robust and prognostic Immune Related Gene signature for cervical squamous cell carcinoma. Front Mol Biosci. 2021;8:1–15.
doi: 10.3389/fmolb.2021.625470
Song W, Ren J, Xiang R, Yuan W, Fu T. Cross-talk between m(6)A- and m(5)C-Related lncRNAs to Construct a Novel signature and predict the Immune Landscape of Colorectal Cancer patients. Front Immunol. 2022;13:1–16.
Doncheva NT, Morris JHG, Jensen J. Cytoscape StringApp: Network Analysis and Visualization of Proteomics Data. J Proteome Res. 2019;18(2):623–32.
pubmed: 30450911
doi: 10.1021/acs.jproteome.8b00702
Zhang X, Ren L, Yan X, Shan Y, Liu L, Zhou J, Kuang Q, Li M, Long H, Lai W. Identification of immune-related lncRNAs in periodontitis reveals regulation network of gene-lncRNA-pathway-immunocyte. Int Immunopharmacol. 2020;84:1–12.
doi: 10.1016/j.intimp.2020.106600
Goeman JJ. L1 penalized estimation in the Cox proportional hazards model. Biometrical J Biometrische Z. 2010;52(1):70–84.
doi: 10.1002/bimj.200900028
Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–180.
pubmed: 25846097
pmcid: 4465353
doi: 10.1016/S1470-2045(14)71116-7
Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41(Database issue):D955–961.
pubmed: 23180760
Zhu Y, Meng X, Ruan X, Lu X, Yan F, Wang F. Characterization of Neoantigen Load Subgroups in gynecologic and breast cancers. Front Bioeng Biotechnol. 2020;8:1–11.
doi: 10.3389/fbioe.2020.00702
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W. Smyth GK: limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):1–13.
doi: 10.1093/nar/gkv007
Aalijahan H, Ghorbian S. Long non-coding RNAs and cervical cancer. Exp Mol Pathol. 2019;106:7–16.
pubmed: 30471246
doi: 10.1016/j.yexmp.2018.11.010
Zhu H, Zhu H, Tian M, Wang D, He J, Xu T. DNA methylation and hydroxymethylation in Cervical Cancer: diagnosis, prognosis and treatment. Front Genet. 2020;11:1–12.
Pan J, Xu L, Pan H. Development and validation of an m6A RNA methylation Regulator-based signature for prognostic prediction in cervical squamous cell carcinoma. Front Oncol. 2020;10:1–8.
doi: 10.3389/fonc.2020.01444
Ma X, Li Y, Wen J, Zhao Y. m6A RNA methylation regulators contribute to malignant development and have a clinical prognostic effect on cervical cancer. Am J Translational Res. 2020;12(12):8137–46.
Wu L, Liao W, Wang X, Zhao Y, Pang J, Chen Y, Yang H, He Y. Expression, prognosis value, and immune infiltration of lncRNA ASB16-AS1 identified by pan-cancer analysis. Bioengineered. 2021;12(2):10302–18.
pubmed: 34709970
pmcid: 8810074
doi: 10.1080/21655979.2021.1996054
Liu W, Zhuang R, Feng S, Bai X, Jia Z, Kapora E, Tan W. Long non-coding RNA ASB16-AS1 enhances cell proliferation, migration and invasion via functioning as a ceRNA through miR-1305/Wnt/β-catenin axis in cervical cancer. Biomed Pharmacotherapy = Biomedecine Pharmacotherapie. 2020;125:1–10.
Liu W, Wang QP, Guo J. Prognostic significance of lncRNA DANCR expression in human cancers: a systematic review and meta-analysis. Biosci Rep. 2021;41(8):1–9.
doi: 10.1042/BSR20181627
Hu C, Han Y, Zhu G, Li G, Wu X. Krüppel-like factor 5-induced overexpression of long non-coding RNA DANCR promotes the progression of cervical cancer via repressing microRNA-145-3p to target ZEB1. Cell Cycle (Georgetown Tex). 2021;20(14):1441–54.
pubmed: 34233586
doi: 10.1080/15384101.2021.1941625
Cao L, Jin H, Zheng Y, Mao Y, Fu Z, Li X, Dong L. DANCR-mediated microRNA-665 regulates proliferation and metastasis of cervical cancer through the ERK/SMAD pathway. Cancer Sci. 2019;110(3):913–25.
pubmed: 30582654
pmcid: 6398927
doi: 10.1111/cas.13921
Huang X, Shi H, Shi X, Jiang X. LncRNA FBXL19-AS1 promotes proliferation and metastasis of cervical cancer through upregulating COL1A1 as a sponge of miR-193a-5p. J Biol Res (Thessalonike Greece). 2021;28(1):1–14.
Wan S, Ni G, Ding J, Huang Y. Long noncoding RNA FBXL19-AS1 expedites cell growth, Migration and Invasion in Cervical Cancer by miR-193a-5p/PIN1 signaling. Cancer Manage Res. 2020;12:9741–52.
doi: 10.2147/CMAR.S262215
Dai S, Yao D. An immune-associated ten-long noncoding RNA signature for predicting overall survival in cervical cancer. Translational cancer Res. 2021;10(12):5295–306.
doi: 10.21037/tcr-21-2390
Li S, Han Y, Liang X, Zhao M. LINC01089 inhibits the progression of cervical cancer via inhibiting miR-27a-3p and increasing BTG2. J Gene Med. 2021;23(1):1–10.
doi: 10.1002/jgm.3280
Qi H, Lu L, Wang L. Long noncoding RNA ST7-AS1 Upregulates TRPM7 expression by sponging microRNA-543 to promote Cervical Cancer Progression. OncoTargets Therapy. 2020;13:7257–69.
pubmed: 32801754
pmcid: 7394585
doi: 10.2147/OTT.S253868
Ramilowski JA, Yip CW, Agrawal S, Chang JC, Ciani Y, Kulakovskiy IV, Mendez M, Ooi JLC, Ouyang JF, Parkinson N, et al. Functional annotation of human long noncoding RNAs via molecular phenotyping. Genome Res. 2020;30(7):1060–72.
pubmed: 32718982
pmcid: 7397864
doi: 10.1101/gr.254219.119
Xu F, Shen J, Xu S. Integrated Bioinformatical Analysis identifies GIMAP4 as an Immune-related prognostic Biomarker Associated with Remodeling in Cervical Cancer Tumor Microenvironment. Front cell Dev Biology. 2021;9:1–13.
Chen Q, Qiu B, Zeng X, Hu L, Huang D, Chen K, Qiu X. Identification of a tumor microenvironment-related gene signature to improve the prediction of cervical cancer prognosis. Cancer Cell Int. 2021;21(1):1–16.
pubmed: 33397383
pmcid: 7784262
Zhou B, Lawrence T, Liang Y. The role of Plasmacytoid dendritic cells in cancers. Front Immunol. 2021;12:1–10.
doi: 10.3389/fimmu.2021.749190
Liu Y, Li L, Li Y, Zhao X. Research Progress on Tumor-Associated macrophages and inflammation in Cervical Cancer. Biomed Res Int. 2020;2020:1–6.
Zhou B, Li T, Xie R, Zhou J, Liu J, Luo Y, Zhang X. CircFAT1 facilitates cervical cancer malignant progression by regulating ERK1/2 and p38 MAPK pathway through miR-409-3p/CDK8 axis. Drug Dev Res. 2021;82(8):1131–43.
pubmed: 33818788
doi: 10.1002/ddr.21816
Xu J, Pan Q, Ju W. Ras inhibition by zoledronic acid effectively sensitizes cervical cancer to chemotherapy. Anticancer Drugs. 2019;30(8):821–7.
pubmed: 30882399
doi: 10.1097/CAD.0000000000000779